Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BNTX | PRESS-RELEASE | neutral | 4/10 | BioNTech announced 16 abstracts across 10 tumor types at ESMO 2026, including first data from the global Phase 2 ROSETTA | Oct 19, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 7/10 | Zentalis announced positive overall survival data from an interim analysis of the DENALI Part 1b study for azenosertib i | Oct 18, 2026 |
| IRON | PRESS-RELEASE | mixed | 7/10 | Disc Medicine announced a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in er | Oct 18, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 2/10 | Zenas BioPharma granted 74,900 RSUs to new hires as an inducement material to employment, vesting over four years. This | Oct 16, 2026 |
| KRRO | PRESS-RELEASE | neutral | 2/10 | Korro Bio granted non-statutory stock options to two new employees as an inducement to employment, covering 4,000 shares | Oct 16, 2026 |
| VTRS | PRESS-RELEASE | bullish | 6/10 | Viatris received FDA approval for RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in ad | Oct 16, 2026 |
| SCNI | PRESS-RELEASE | bearish | 5/10 | Scinai closed a $4.0M private placement and warrant inducement, issuing ~2.46M ADSs and warrants for up to ~5.0M additio | Oct 16, 2026 |
| CRIS | PRESS-RELEASE | bearish | 6/10 | Curis announced an $8.5 million private placement with existing healthcare-focused institutional investors, selling ~16. | Oct 16, 2026 |
| CBIO | PRESS-RELEASE | neutral | 4/10 | Crescent Biopharma provided a clinical pipeline update, highlighting completion of dose escalation in the global Phase 1 | Oct 15, 2026 |
| MGNX | PRESS-RELEASE | neutral | 3/10 | MacroGenics announced dosing of the first patient in a Phase 1 study of MGC030, a first-in-class ADC for advanced solid | Oct 15, 2026 |
| MYGN | PRESS-RELEASE | neutral | 1/10 | Myriad Genetics, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 15, 2026 |
| IRD | PRESS-RELEASE | bullish | 6/10 | Opus Genetics presented interim clinical data at Retina in Rio 2026 for its two lead gene therapy programs. OPGx-BEST1 s | Oct 15, 2026 |
| AVXL | PRESS-RELEASE | neutral | 4/10 | Anavex received FDA clearance to proceed with its IND for blarcamesine (ANAVEX®2-73) in Fragile X syndrome, enabling a P | Oct 15, 2026 |
| LLY | PRESS-RELEASE | neutral | 1/10 | Eli Lilly and Company announced it will host a conference call on October 29, 2026 to discuss its Q3 2026 results. | Oct 15, 2026 |
| EDSA | PRESS-RELEASE | neutral | 4/10 | Edesa Biotech announced FDA clearance of its IND for EB06, a monoclonal antibody targeting CXCL10, enabling expansion of | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 5/10 | Recursion Pharmaceuticals announced that Sanofi has optioned the first development candidate from their multi-program co | Oct 15, 2026 |
| VVOS | PRESS-RELEASE | neutral | 5/10 | Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12M) to acquire an 11% eq | Oct 15, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI announced independent lab results showing SteraMist iHP sharply reduces Listeria monocytogenes in biofilm (flat sur | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | bearish | 6/10 | Recursion Pharmaceuticals priced a $200 million underwritten public offering of 61.54 million shares at $3.25 per share, | Oct 15, 2026 |
| RXRX | PRESS-RELEASE | mixed | 6/10 | Recursion Pharmaceuticals announced a $200 million underwritten common stock offering alongside positive clinical data u | Oct 15, 2026 |
| JSPR | PRESS-RELEASE | bearish | 7/10 | Jasper Therapeutics announced completion of enrollment in the IgAN cohort of its Phase 2 basket study for vensobafusp al | Oct 15, 2026 |
| TRAX | PRESS-RELEASE | bearish | 6/10 | First Tracks Biotherapeutics announced a $200M private placement of 6.1M shares at $32.75/share, with proceeds for gener | Oct 15, 2026 |
| TARA | PRESS-RELEASE | neutral | 3/10 | Protara Therapeutics completed enrollment of the Phase 2b dose confirmation cohort (24 patients) in the THRIVE-3 registr | Oct 15, 2026 |
| HUMA | PRESS-RELEASE | bullish | 5/10 | Humacyte provided a Q3 2026 commercial update highlighting accelerating Symvess adoption, with hospitals ordering the pr | Oct 15, 2026 |
| HELP | PRESS-RELEASE | neutral | 3/10 | Helus Pharma appointed Dr. Suresh Durgam, a CNS drug-development executive with FDA approval experience (CAPLYTA), to it | Oct 15, 2026 |
| PVLA | PRESS-RELEASE | neutral | 4/10 | Palvella Therapeutics announced poster presentations at the PeDRA Annual Conference featuring new pediatric analyses fro | Oct 15, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc announced a strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance, while | Oct 15, 2026 |
| LGND | PRESS-RELEASE | neutral | 1/10 | Ligand Pharmaceuticals announced it will report its Q3 2026 results on October 29, 2026. | Oct 15, 2026 |
| ADMA | PRESS-RELEASE | neutral | 4/10 | ADMA Biologics announced a peer-reviewed publication in Frontiers in Cardiovascular Medicine detailing data from its opt | Oct 15, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in Waldenst | Oct 15, 2026 |